MX338931B - Composiciones y metodo para tratar gliobastoma (gbm). - Google Patents
Composiciones y metodo para tratar gliobastoma (gbm).Info
- Publication number
- MX338931B MX338931B MX2012007850A MX2012007850A MX338931B MX 338931 B MX338931 B MX 338931B MX 2012007850 A MX2012007850 A MX 2012007850A MX 2012007850 A MX2012007850 A MX 2012007850A MX 338931 B MX338931 B MX 338931B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- polynucleotide sequence
- treating glioblastoma
- fas
- Prior art date
Links
- 208000005017 glioblastoma Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 206010018338 Glioma Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 208000029824 high grade glioma Diseases 0.000 abstract 1
- 201000011614 malignant glioma Diseases 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1077—Beam delivery systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1087—Ions; Protons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28222810P | 2010-01-05 | 2010-01-05 | |
| US28224810P | 2010-01-07 | 2010-01-07 | |
| PCT/IL2011/000009 WO2011083466A1 (en) | 2010-01-05 | 2011-01-05 | Compositions and methods for treating glioblastoma gbm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012007850A MX2012007850A (es) | 2012-12-05 |
| MX338931B true MX338931B (es) | 2016-05-06 |
Family
ID=44305240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007850A MX338931B (es) | 2010-01-05 | 2011-01-05 | Composiciones y metodo para tratar gliobastoma (gbm). |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20130209450A1 (enExample) |
| EP (1) | EP2521777B1 (enExample) |
| JP (2) | JP6151515B2 (enExample) |
| KR (1) | KR101810257B1 (enExample) |
| AU (1) | AU2011204407B2 (enExample) |
| CA (1) | CA2786377C (enExample) |
| MX (1) | MX338931B (enExample) |
| NZ (1) | NZ601325A (enExample) |
| SG (2) | SG10201500048SA (enExample) |
| WO (1) | WO2011083466A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| NZ532348A (en) | 2001-10-19 | 2006-06-30 | Vascular Biogenics Ltd | Polynucleotide constructs comprising ligand binding domains, effector domains of apoptosis signaling molecules and a promoter or enhancer and their use in gene therapy |
| JP5513885B2 (ja) | 2006-07-31 | 2014-06-04 | ヴァスキュラー バイオジェニックス リミテッド | ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用 |
| CN104788492A (zh) | 2008-11-06 | 2015-07-22 | 脉管生物生长有限公司 | 氧化的脂质化合物和其用途 |
| JP6151515B2 (ja) | 2010-01-05 | 2017-06-21 | バスキュラー バイオジェニックス リミテッド | 神経膠芽腫ｇｂｍを治療するための組成物および方法 |
| US9567605B2 (en) | 2010-01-05 | 2017-02-14 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
| SI2908865T1 (sl) * | 2012-10-17 | 2019-02-28 | Vascular Biogenics Ltd. | Adenovirus, ki izraža Fas himero in uporaba le-tega v postopkih zdravljenja raka |
| WO2014118643A2 (en) | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| US10258810B2 (en) | 2013-09-27 | 2019-04-16 | Mevion Medical Systems, Inc. | Particle beam scanning |
| US10675487B2 (en) | 2013-12-20 | 2020-06-09 | Mevion Medical Systems, Inc. | Energy degrader enabling high-speed energy switching |
| US9962560B2 (en) | 2013-12-20 | 2018-05-08 | Mevion Medical Systems, Inc. | Collimator and energy degrader |
| US9661736B2 (en) | 2014-02-20 | 2017-05-23 | Mevion Medical Systems, Inc. | Scanning system for a particle therapy system |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| EP3223824B1 (en) | 2014-11-26 | 2021-01-06 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
| US10786689B2 (en) | 2015-11-10 | 2020-09-29 | Mevion Medical Systems, Inc. | Adaptive aperture |
| US20170273926A1 (en) * | 2016-03-24 | 2017-09-28 | Orbus Therapeutics, Inc. | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas |
| CN109803723B (zh) | 2016-07-08 | 2021-05-14 | 迈胜医疗设备有限公司 | 一种粒子疗法系统 |
| NZ752894A (en) | 2016-10-06 | 2023-05-26 | Orbus Therapeutics Inc | Formulations for administration of eflornithine |
| US11103730B2 (en) | 2017-02-23 | 2021-08-31 | Mevion Medical Systems, Inc. | Automated treatment in particle therapy |
| US10653892B2 (en) | 2017-06-30 | 2020-05-19 | Mevion Medical Systems, Inc. | Configurable collimator controlled using linear motors |
| US20210322574A1 (en) | 2017-10-20 | 2021-10-21 | Vascular Biogenics Ltd. | Diagnostic methods for anti-angiogenic agent therapy |
| WO2020185543A1 (en) | 2019-03-08 | 2020-09-17 | Mevion Medical Systems, Inc. | Collimator and energy degrader for a particle therapy system |
| BR112021017780A2 (pt) * | 2019-03-13 | 2022-02-01 | Vascular Biogenics Ltd | Métodos de terapia anti-tumor |
| SG11202109441UA (en) | 2019-04-12 | 2021-09-29 | Vascular Biogenics Ltd | Methods of anti-tumor therapy |
| EP4326365A4 (en) * | 2021-05-19 | 2025-03-12 | Alcyone Therapeutics, Inc. | FLUID DELIVERY SYSTEMS AND TREATMENT METHODS |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1707631A3 (en) | 1996-11-20 | 2006-12-27 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US6204055B1 (en) * | 1999-04-12 | 2001-03-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Fas mediated signaling |
| IL130608A0 (en) | 1999-06-23 | 2000-06-01 | Compugen Ltd | Novel nucleic and amino acid sequence |
| US6867022B1 (en) | 2000-01-21 | 2005-03-15 | Regents Of The University Of Michigan | Replication deficient adenovirus vectors and methods of making and using them |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| DK2186530T3 (da) | 2000-11-17 | 2013-07-29 | Vascular Biogenics Ltd | Promotere, der udviser endothelcellespecificitet og fremgangsmåder til anvendelse heraf |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US20100282634A1 (en) | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| US20070286845A1 (en) * | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US8039261B2 (en) | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US7067649B2 (en) | 2000-11-17 | 2006-06-27 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| NZ532348A (en) | 2001-10-19 | 2006-06-30 | Vascular Biogenics Ltd | Polynucleotide constructs comprising ligand binding domains, effector domains of apoptosis signaling molecules and a promoter or enhancer and their use in gene therapy |
| US20080063656A1 (en) | 2004-08-09 | 2008-03-13 | Emini Emilio A | Adenoviral Vector Compositions |
| WO2006079176A1 (en) | 2005-01-28 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| WO2007044441A2 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases |
| JP5513885B2 (ja) | 2006-07-31 | 2014-06-04 | ヴァスキュラー バイオジェニックス リミテッド | ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用 |
| US9567605B2 (en) | 2010-01-05 | 2017-02-14 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
| JP6151515B2 (ja) | 2010-01-05 | 2017-06-21 | バスキュラー バイオジェニックス リミテッド | 神経膠芽腫ｇｂｍを治療するための組成物および方法 |
| JP6009357B2 (ja) | 2010-01-12 | 2016-10-19 | バスキュラー バイオジェニックス リミテッド | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 |
| SI2908865T1 (sl) | 2012-10-17 | 2019-02-28 | Vascular Biogenics Ltd. | Adenovirus, ki izraža Fas himero in uporaba le-tega v postopkih zdravljenja raka |
-
2011
- 2011-01-05 JP JP2012547587A patent/JP6151515B2/ja not_active Expired - Fee Related
- 2011-01-05 KR KR1020127020567A patent/KR101810257B1/ko not_active Expired - Fee Related
- 2011-01-05 US US13/520,452 patent/US20130209450A1/en not_active Abandoned
- 2011-01-05 EP EP11731735.4A patent/EP2521777B1/en active Active
- 2011-01-05 NZ NZ601325A patent/NZ601325A/en not_active IP Right Cessation
- 2011-01-05 MX MX2012007850A patent/MX338931B/es active IP Right Grant
- 2011-01-05 SG SG10201500048SA patent/SG10201500048SA/en unknown
- 2011-01-05 CA CA2786377A patent/CA2786377C/en active Active
- 2011-01-05 SG SG2012049573A patent/SG182366A1/en unknown
- 2011-01-05 WO PCT/IL2011/000009 patent/WO2011083466A1/en not_active Ceased
- 2011-01-05 AU AU2011204407A patent/AU2011204407B2/en not_active Ceased
-
2013
- 2013-03-14 US US13/826,303 patent/US10369196B2/en not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001588A patent/JP2016128440A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120120942A (ko) | 2012-11-02 |
| US20130209450A1 (en) | 2013-08-15 |
| EP2521777A4 (en) | 2014-04-02 |
| WO2011083466A1 (en) | 2011-07-14 |
| MX2012007850A (es) | 2012-12-05 |
| NZ601325A (en) | 2014-09-26 |
| JP2016128440A (ja) | 2016-07-14 |
| SG10201500048SA (en) | 2015-03-30 |
| SG182366A1 (en) | 2012-08-30 |
| CA2786377A1 (en) | 2011-07-14 |
| US20130303595A1 (en) | 2013-11-14 |
| KR101810257B1 (ko) | 2017-12-18 |
| AU2011204407B2 (en) | 2015-05-07 |
| US10369196B2 (en) | 2019-08-06 |
| JP2013516456A (ja) | 2013-05-13 |
| CA2786377C (en) | 2018-02-27 |
| JP6151515B2 (ja) | 2017-06-21 |
| AU2011204407A1 (en) | 2012-08-09 |
| EP2521777A1 (en) | 2012-11-14 |
| EP2521777B1 (en) | 2016-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX338931B (es) | Composiciones y metodo para tratar gliobastoma (gbm). | |
| NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
| MX2016007063A (es) | Peptidos terapeuticos. | |
| RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
| MY172457A (en) | Composition and methods for highly efficient gene transfer using aav capsid variants | |
| IN2014DN01811A (enExample) | ||
| TN2012000512A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| MY195289A (en) | Anti IL-36R Antibodies | |
| NZ753018A (en) | Conjugated antisense compounds and their use | |
| IN2014DN06104A (enExample) | ||
| MX2010003013A (es) | Inhibicion de angiogenesis. | |
| PH12013500543A1 (en) | Breast cancer therapeutics | |
| MX356091B (es) | Composiciones de escoria que comprenden látex y métodos de uso. | |
| WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
| TN2012000511A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies | |
| MX2019007057A (es) | Composiciones de adenovirus. | |
| MX2012001306A (es) | Inhibicion de matastasis de tumor. | |
| TN2011000403A1 (en) | Compositions and methods for extended therapy wiht aminopyridines | |
| EA201300876A1 (ru) | Мутантная целлобиогидролаза | |
| PH12013501205A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| IN2014DN09963A (enExample) | ||
| EA033437B1 (ru) | Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний | |
| IN2014DN03298A (enExample) | ||
| GB201118201D0 (en) | Novel peptides | |
| MX2014001736A (es) | Inhibicion de angiogenesis en tumores refractarios. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |